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Head and neck paragangliomas are tumors arising from specialized neural crest cells. Prominent locations are the
carotid body along with the vagal, jugular, and tympanic glomus. Head and neck paragangliomas are slowly
growing tumors, with some carotid body tumors being reported to exist for many years as a painless lateral mass on
the neck. Symptoms depend on the specific locations. In contrast to paraganglial tumors of the adrenals, abdomen
and thorax, head and neck paragangliomas seldom release catecholamines and are hence rarely vasoactive. Petrous
bone, jugular, and tympanic head and neck paragangliomas may cause hearing loss. The internationally accepted
clinical classifications for carotid body tumors are based on the Shamblin Class I–III stages, which correspond to
postoperative permanent side effects. For petrous-bone paragangliomas in the head and neck, the Fisch
classification is used. Regarding the molecular genetics, head and neck paragangliomas have been associated
with nine susceptibility genes: NF1, RET, VHL,S DHA, SDHB, SDHC, SDHD, SDHAF2 (SDH5), and TMEM127. Hereditary
HNPs are mostly caused by mutations of the SDHD gene, but SDHB and SDHC mutations are not uncommon in such
patients. Head and neck paragangliomas are rarely associated with mutations of VHL, RET, or NF1. The research on
SDHA, SDHAF2 and TMEM127 is ongoing. Multiple head and neck paragangliomas are common in patients with
SDHD mutations, while malignant head and neck paraganglioma is mostly seen in patients with SDHB mutations.
The treatment of choice is surgical resection. Good postoperative results can be expected in carotid body tumors of
Shamblin Class I and II, whereas operations on other carotid body tumors and other head and neck paragangliomas
frequently result in deficits of the cranial nerves adjacent to the tumors. Slow growth and the tendency of
hereditary head and neck paragangliomas to be multifocal may justify less aggressive treatment strategies.
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INTRODUCTION
Head and neck paragangliomas (HNPs) are tumors of the
autonomic system. They arise from chromaffin cells of the
parasympathetic paraganglia of the skull base and neck, and
are also called glomus tumors (1–5). Most well known is the
tumor of the glomus caroticum, the carotid body tumor
(CBT). HNP surgery is a challenge to the surgeon because of
the tumor’s location in the vicinity of important blood
vessels and cranial nerves. As well as pre-operative
impairment of nerve function, surgery may result in deficits
of cranial nerves VII, VIII, IX, X, XI, and XII.
In this review, we present an overview of the clinical
presentation and radiologic imaging of HNPs, topographi-
cal classification of HNPs, and recent advances in the
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19genetics of HNPs in the context of nine susceptibility genes
predisposing to tumors of the paraganglial system. These
genetic data not only enrich our understanding of HNPs,
but also provide us with a tool for risk assessment of tumors
outside the head and neck region.
PREVALENCE
HNPs are rare tumors, representing less than 0.5% of all
head and neck tumors. Approximately 3% of paraganglio-
mas occur in the head and neck area (4); other estimates
suggest that 1 in 30,000 head and neck tumors are HNPs (5).
TOPOGRAPHY
Most HNPs arise in the bifurcation of the carotid artery
(i.e. CBTs). Vagal paragangliomas arise from the autonomic
nervous part of the vagal nerve (cranial nerve X). HNPs
arising in the petrous bone originate from the tympanic
glomus or the jugular glomus. When these tumors cannot be
differentiated, they are referred to as jugulotympanic
paragangliomas. Given the extensive spreading of the
autonomic nervous structure, HNPs can arise at other
locations, such as the ciliary glomus or laryngic glomus.
SIGNS AND SYMPTOMS
HNPs are space-occupying tumors. Signs and symptoms
are induced by the topography of the anatomical structures
from which the tumors originate. In contrast to extra-adrenal,
abdominal, and thoracic pheochromocytomas, HNPs rarely
secrete active substances. Only 1–3% of HNPs are vasoactive
and associated with elevated catecholamines. Such tumors
can induce tachycardia, hypertension and sweating attacks.
Carotid body tumors (CBTs)
CBTs arise from paraganglia located within the covering of
the carotid artery in the neck. CBTs often remain clinically
silent before presenting as a painless, slowly enlarging mass
in the lateral neck (1,6,7). Approximately 60–70% of all CBTs
take this route of clinical presentation (6,7). The initial
symptoms can also be a pulsating mass in the neck. CBTs
can be moved horizontally rather than vertically, a finding
known as a positive Fontaine’s sign (1). Large CBTs may
induce dysfunction of the vagal nerve and, less frequently, of
cranial nerves IX, XI, and XII. Occasionally, Horner’s
syndrome or deficits of the facial nerve may result from
extremely large tumors (1,6). Sometimes a carotid bruit or a
pulsating mass can be detected.
Vagal paragangliomas
Vagal paragangliomas (VPs) are located more cephalad in the
neck, between the jugular vein and the internal carotid artery,
sometimes extending to the base of the skull through the jugular
foramen or posterior to the mastoid tip (8). The symptoms of a
VP depend on the location of the tumor along the vagal nerve
from the skull base to the lower neck (8). Most VPs arise from
the glomus nodosum, that is, the inferior ganglion. Typically,
VPs present with an asymptomatic neck mass behind the angle
of the mandible. Other symptoms of VPs are pulsatile tinnitus
or ringing in the ear heard with each heartbeat (9). At times, this
can be heard by placing the stethoscope over the ear. Less than
50% of VPs present with deficits of cranial nerves, which
manifest as hoarseness (X), dysphagia (IX), shoulder drop (XI),
nasal reflux of fluids, aspiration and hemiatrophy of the tongue
(XII) (10,11). Intracranial extension, which is the main cause of
death, occurs in 22% of the cases (4). Oropharyngeal involve-
ment caused by bulging of the pharyngeal wall into the
pharyngeal lumen and medial displacement of the tonsil, may
occasionally be observed.
Temporal paragangliomas
Temporal paragangliomas entail tympanic and jugular
paragangliomas. They arise from structures in close vicinity
and are sometimes summarized in one group.
Tympanic paragangliomas
Tympanic paragangliomas (TPs) are mostly small-sized
tumors originating in the middle ear. These tumors become
symptomatic as pulsatile tinnitus in the vast majority of
patients. Hearing loss is initially present in about half of
patients (1,3–5,12). Most TPs are visible as a vascular middle
ear mass. They are diagnosed by careful examination of the
tympanic membrane and identification of the tumor
through the translucent eardrum. Introducing positive
pressure in the ear canal stops the pulsations of the tumor.
Frequently, it is impossible to visualize the entire tumor
clinically, thus computed tomography (CT) or magnetic
resonance imaging (MRI) scans are diagnostic.
Jugular paragangliomas
Jugular paragangliomas (JPs) arise from paraganglia in or
around the jugular bulb (12,13). Occlusion of venous flow
happens when these tumors increase in size. Consequently,
venous blood from the brain shifts toward the unaffected
sigmoidsinusandjugularbulb.Symptomsaresimilartothose
of TP. Pulsatile tinnitus is a frequent symptom. A bruit can be
heard by placing a stethoscope over the ear. Conductive
hearing loss is seen with progression of the tumor, which
either causes impairment of vibration of the ossicles or
invades the bones behind the eardrum. Sensorineural hearing
loss and/or dizziness is reported by patients when the tumor
has invaded the inner ear. Occasionally, JPs can cause deficits
of other cranial nerves and create dysfunctional swallowing
and huskiness of the voice. However, due to the relatively
slow growth, the swallowing mechanism and vocal cord
function of the opposite side may initially compensate and
mask the disease symptoms. When these tumors grow, they
can also invade the facial nerve leading to facial paralysis, or
they can encompass the hypoglossal nerve, leading to
paralysis of half of the tongue. Further growth can lead to
compression of the brain and/or brainstem.
RADIOLOGY
B-mode sonography and color duplex sonography are
inexpensive, noninvasive diagnostic tools that are often
used as the first imaging step for cervical HNPs (1,14). A
CBT is usually sonographically seen as a solid, well-defined,
hypoechoic mass with a splaying of the carotid bifurcation
(1). The external carotid artery (ECA) is usually displaced
anteromedially, and the internal carotid artery (ICA) is
typically displaced posterolaterally (15).
VPs tend to displace both the ECA and the ICA anteriorly.
The internal jugular vein is typically compressed and
displaced posteriorly (15). In large VPs there may also be a
splaying of the carotid bifurcation, thereby mimicking a CBT.
In color duplex sonography scans, cervical HNPs present
as hypervascular tumors in most cases. It is important to
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20mention, however, that absence of hypervascularity does
not exclude a cervical HNP (16). In a study on 18 CBTs, 15
(83.3%) presented as a hypervascular mass in color duplex
sonography scans (16).
Carotid, tympanic, and jugular paragangliomas are easily
detected using CT and MR angiography. They contain many
arterio-venous shunts and show strong enhancement with
CT-angiography. Using time-resolved contrast-enhanced
MR-angiography, they are detected in the early arterial
phase (Figure 2D). Tympanic paragangliomas are seen on
high resolution CT images of the petrous bone as a focal
soft-tissue mass in the tympanon (17). CT is superior for the
detection of bone destruction in the temporal bone (18). For
jugular paragangliomas both MR (17) and CT (19) are
recommended. CT-angiography depicts the anatomy more
accurately than MR-angiography because of the better
spatial resolution (19). However, contrast-enhanced MR-
angiography is better suited for screening and detection of
multiple lesions. Both cross-sectional methods can be used
for operative navigation. Pre-operative embolization of the
paragangliomas aims for a reduction of blood loss during
operation, but the literature is controversial (7,20).
NUCLEAR MEDICINE IMAGING
HNPs typically show avid uptake with different functional
imaging techniques, namely 18F-fluorodihydroxyphenylala-
nine (18F-FDOPA) positron emission tomography/com-
puted tomography (PET/CT); 18F-fluorodopamine (18F-
FDA) PET/CT and 123I-metaiodobenzylguanidine (123I-
MIBG) scintigraphy; the latter is paraganglioma specific.
Furthermore, somatostatin receptor imaging has a sensitivity
of greater than 90% for HNP (21) using 111In-octreotide
scintigraphy. Positron emitting somatostatin receptor ima-
ging agents, such as 68Ga-DOTA-peptides [e.g. 68Ga-DOTA-
TATE (DOTA-Tyr3-Thr8-octreotide)] have shown promising
sensitivities in small series (22). It offers an additional
advantage in identifying patients likely to benefit from
therapy with 90Y-labelled DOTA-TATE. 18F-FDOPA PET,
in particular, has been proved to be highly sensitive in
different series and may be considered a good imaging
technique for HNPs (23) but may perform poorly in SDHB-
associated metastatic disease; under these conditions, 18F-
FDG-PET/CT provides higher sensitivities (24).
CLINICAL CLASSIFICATION OF CAROTID BODY
TUMORS
CBTs are usually classified using the criteria described by
Shamblin and co-workers (25).
Shamblin classification
Shamblin Class I CBTs are localized tumors with splaying of
the carotid bifurcation, but little attachment to the carotid
vessels. Complete surgical resection is generally possible with
only minimal risk of vascular or cranial nerve complications (1).
Shamblin Class II CBTs partially surround the carotid
vessels and complete resection is more challenging.
Shamblin class III CBTs intimately surround the carotid.
Complete resection is very challenging, and often requires
temporary interruption of the cerebral circulation for
vascular reconstruction. The risk of permanent vascular
and neural defects is significantly higher than for Class I
and Class II tumors (26). Figure 1A–C demonstrates three
Shamblin classes of CBTs.
CLINICAL CLASSIFICATION OF TEMPORAL
PARAGANGLIOMAS
CT is almost crucial to evaluate temporal paragangliomas.
The extent of temporal bone destruction is used to classify
these tumors according to the Fisch classification (Table 1)
(27).
Figure 1 - Shamblin classification. The Shamblin classification is based on involvement of the carotid arteries, which are shown by white
arrows in A–C. The tumors are indicated by yellow arrows. (A) CBT (class I): the axial T2-weighted MRI shows a CBT in a typical location.
Bulging of the left carotid bifurcation without any encasement of the carotid vessels. (B) CBT (class II): axial T2-weighted MRI showing a
right-sided CBT with a partial encasement of the internal and external carotid artery. (C) CBT (class III): an axial slice of CT-angiography
reveals a huge left-sided CBT with a complete encasement of the carotid vessels. In this case, bone destruction of the skull base,
attributed to the enormous CBT, was also detected by CT (not shown).
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21Fisch classification
TPs arise from paraganglia along the tympanic plexus on
the promontory (table 2, figure 2). Fisch class A tumors are
limited to the promontory and the mesotympanon. In Fisch
class B tumors, there is an invasion of the hypotympanon.
Class B paragangliomas often surround, and frequently
destroy, the ossicles. In TPs, the bone over the jugular bulb
is intact. JPs arise from paraganglia in, or around, the jugular
bulb. There is bone destruction around the jugular bulb in all
patients with JPs. Fisch class C tumors are further classified
into subgroupsC1–C4 according to the extent ofbone erosions
around the carotid foramen, the carotid canal and the foramen
lacerum. Patients with Fisch class D tumors have intracranial
extension of the paraganglioma. Further subclassification is
based on the extradural versus intradural extension and the
depth of intracranial invasion. It is important to note that for
JPs, Fisch class D cannot be used separately without also using
the subclassification for class C. In paragangliomas with
intracranial extension, the D classification should always be
accompanied by a C classification (e.g. C3Di2). Fisch classifica-
tion before surgery is essential as the operative approach is
determined by the tumor stage.
MOLECULAR GENETICS CLASSIFICATION
Current genetic classification is still incomplete and merits
revision. To date, nine different susceptibility genes have
been identified for tumors of the paraganglial system. The six
relevant genes and associated syndromes are summarized in
Table 3.It isimportant tonotethat some genesarefrequently,
and others rarely, mutated. The succinate dehydrogenase
subunit D (SDHD) gene was first recognized as the
susceptibility gene of paraganglioma syndrome type 1
(PGL 1) in 2000 (28). Subsequently, mutations of the B and
C subunit genes (SDHB and SDHC) were described in
patients with paraganglioma syndromes that were later
designated as PGL type 3 and type 4 (29,30). The suscept-
ibility gene for PGL 2 was identified nine years later (22). The
SDHAF2 gene, also called SDH5, affects flavination of SDHA.
In 2010, the SDHA gene was identified as a tumor suppressor
gene associatedwithparaganglial tumors (31). Also in 2010, a
gene called TMEM127 was found to be mutated in
pheochromocytomas, i.e. exclusively adrenal paraganglial
tumors (32). Meanwhile, it became evident that the spectrum
of TMEM127 mutations extends to HNPs (33). Rarely,
mutations of the well-known genes causing multiple
Figure 2 - Fisch classification. The tumors are indicated by yellow arrows. (A) Tympanic paraganglioma (Fisch class A): axial CT scan of a
tympanic paraganglioma (bone window) on the right promontory. Note the absence of any bony erosion. (B) Tympanic paraganglioma
(Fisch class B): the axial CT scan reveals a left-sided tympanic paraganglioma surrounding and partially destroying the ossicles. The
malleus and stapes could not be discriminated. The tumor had also invaded the hypotympanon. There was no destruction of the bone
wall to the jugular bulb. (C) Jugular paraganglioma (Fisch class C): axial CT scan showing a left-sided jugular paraganglioma. Note the
bone destruction between the jugular bulb and the soft tissue tumor in the hypotympanon. (D) Tympanic paraganglioma (Fisch class
D): time-resolved contrast-enhanced MR-angiography (upper row) depicts an early venous drainage attributed to arterio-venous
fistulas within this tympanic paraganglioma (solid arrows). Coronal CT (lower row left) of the petrous bone shows a soft tissue tumor
with encasement of the ossicles within the whole tympanon, and destruction of the tegmen tympani. Coronal T2-weighted and
contrast enhanced T1-weighted images show a small, but distinct, intracranial but extradural tumor growth on the lateral skull base
(dotted arrows, lower row).
Table 1 - The Shamblin classification of carotid body tumors.
Class Tumor characteristics
I Splaying of the carotid bifurcation with little attachment to the carotid vessels; complete resection with very little morbidity
II Partial surrounding of internal and external carotid artery; complete resection more challenging
III Complete surrounding of the carotid vessels; complete resection often requires major vessel reconstruction
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22endocrine neoplasia type 2 (MEN2), von Hippel-Lindau
disease, and neurofibromatosis type 1 (VHL, RET, and NF1)
may also predispose to HNPs.
The molecular pathomechanisms leading to the develop-
ment of paraganglial tumors is still largely unknown.
Various processes, including activation of hypoxia-induci-
ble factor 1a (HIF1a)-related neoangiogenesis pathways (in
von Hippel-Lindau and in SDHx-associated paraganglioma
syndromes), as well as activation of the Ras oncogene
pathways (in MEN2 and neurofibromatosis type 1) have
been suggested. However, in HNP, the major pathomechan-
ism may stem from the impaired function of mitochondria,
manifesting either as activation of the pseudo-hypoxia
pathway as a result of accumulation of succinate (which
inhibits HIF-alpha prolyl hydroxylases; PHD), leading to
stabilization and activation of HIF-1a (34) or as increased
oxidative stress and genomic instability (35,36). Systematic
evaluation of genes involved in regulation of these path-
ways may reveal additional susceptibility genes. However,
mutation analysis of PHD genes in patients with pheochro-
mocytoma/paraganglioma and renal cell carcinoma
showed no alterations (30).
The likelihood of identifying germline mutations in
patients with HNP has been addressed by several studies.
Our study, published in 2009 (37), with 598 patients with
HNP, found SDHx germline mutations in 31% of patients
(52% SDHD, 34% SDHB, and 14% SDHC). Predictors for a
positive mutation test included family history, previous
adrenal or extra-adrenal pheochromocytoma, multiple
HNPs, age #40 years and male gender. The prevalence of
germline mutations of the VHL, RET, and NF1 genes among
patients with HNP has also been evaluated by our group
through extensive collaboration (38). Twelve patients were
found to have hereditary non-SDHx HNPs out of a total of
809 patients with HNP and 2084 with VHL: 11 with
germline VHL mutations and one with a RET mutation.
The prevalence of hereditary HNP was 5 out of 1,000 in
patients with VHL and nine out of 1,000 in patients
with non-SDHx HNP. A comprehensive literature review
revealed HNPs in five von Hippel-Lindau, two MEN2 and
one neurofibromatosis type 1 patients, who previously had
symptoms characteristic for von Hippel-Lindau disease,
MEN2 or neurofibromatosis type 1. Thus far, the number of
cases associated with mutations in SDHA gene is unknown.
This issue could be addressed from the other end, i.e. the
prevalence of HNPs in carriers of SDHB and SDHD
mutations. This has been recently investigated by a group
from Birmingham in the UK (39), who compared the
penetrance for HNP for mutation carriers of SDHB and
SDHD, and showed that the penetrance for SDHD was
about twice as high as that of SDHB carriers. SDHD
mutations induced HNPs about 20 years earlier compared
with SDHB mutations.
A thorough genotype–phenotype study for different HNP
loci is currently lacking in the literature. What we currently
know is that patients with mutations of SDHB, SDHC, and
SDHD g e n e sm a yd e v e l o pt u m o r si nt h ec a r o t i db o d y
and the vagal, jugular, and tympanic paraganglia (23,28).
Patients with germline mutations of the SDHAF2 gene have
been studied in detail by a Dutch and Spanish group in 2010
(40). So far, only a single mutation has been identified, and
potentially all patients are relatives. CBTs have been shown in a
patientwith aTMEM127germline mutation (33).Morepatients
and details may be expected in forthcoming similar reports.
SURGICAL TREATMENT OF HNP
Surgery of carotid body tumors
In general, treatment options for HNPs comprise surgical
resection, as well as irradiation therapy, stereotactic radio-
surgery and permanent embolization (1,7,41). If necessary
and promising, a combined treatment strategy could be
used. The majority of cases of HNP should undergo
complete surgical resection as this is the only therapeutic
option potentially offering a cure for the patient and is
therefore the treatment of choice (1,6–8,42).
CBTs are the most common type of HNPs, which are
categorized according to the Shamblin classification dis-
cussed above (25). The principal goal of any surgical
attempt concerning CBT is complete tumor resection via a
transcervical approach (1,7,41). With complete surgical
resection, the tumor is controlled locally in 89–100% of
cases (1,43,44). However, the probability of postoperative
cranial nerve dysfunction has to be taken into consideration,
even in cases of successful surgical removal of CBT (1,7). In
a large study on postoperative outcome in 1,181 patients
with CBT, Anand et al. found permanent cranial nerve
deficit in 21.8% of cases (26). Obviously, complication rates
are directly related to tumor size. Therefore, the Shamblin
classification is not only essential for description of tumor
characteristics, but also for the estimation of risks concern-
ing any kind of surgical removal. As the tumor class in the
Shamblin classification increases (i.e. from I to III), surgical
removal of CBT is expected to become more difficult and
challenging. In cases with Shamblin Class III-rated CBTs,
not only does the possibility of cranial nerve deficits
increase but also permanent vascular and neural defects
are frequently seen, as a result of the need for
Table 2 - Classification of jugulotympanic paragangliomas according to Fisch and Mattox.
Class Location and extension of paraganglioma
A Paragangliomas that arise along the tympanic plexus on promontory
B Paragangliomas with invasion of the hypotympanon; cortical bone over jugular bulb intact
C1 Paragangliomas with erosion of the carotid foramen
C2 Paragangliomas with destruction of the vertical carotid canal
C3 Paragangliomas with involvement of the horizontal portion of the carotid canal; foramen lacerum intact
C4 Paragangliomas with invasion of the foramen lacerum and cavernous sinus
De 1/2 Paragangliomas with intracranial but extradural extension; De1/2 according to displacement of the dura
(De1 = less than 2 cm, De2 = more than 2 cm)
Di 1/2/3 Paragangliomas with intracranial and intradural extension; Di1/2/3 according to depth of invasion into the posterior cranial fossa
(Di1 = less than 2 cm, Di 2= between 2 and 4 cm, Di3 = more than 4 cm)
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23intra-operative interruption of the cerebral circulation for
complete tumor resection (1,6).
Surgery of vagal paragangliomas
Similar to CBTs, most authorities prefer surgical resection
of VPs (6–8,42,45). If surgical removal of VP is successfully
performed, local tumor control can be achieved in up
to 100% of cases (43,44,46). Postoperative cranial nerve
dysfunction is considered a major complication of transcer-
vical surgical resection of these tumors (7,8). Unfortunately,
in most cases of VP, it is necessary to sacrifice the vagal
nerve intra-operatively (47). A promising study by Miller et
al. demonstrated higher preservation rates of the vagal
nerve by microsurgical techniques during surgical removal
(8). As for CBTs, the rate of surgical complications in VP
also increases with tumor size, but, unlike CBT, there exists
no generally accepted classification system for VP (1).
Therefore, estimation of possible postoperative complica-
tions is solely dependent on the surgeon’s experience and
pre-operative imaging.
Surgery of skull base paragangliomas
Paragangliomas of the temporal bone are usually differ-
entiated into TPs and JPs, based on the Fisch classification
(27). Using this classification, the feasibility of (complete)
surgical resection can be estimated by the surgeon.
Whenever possible, surgical resection is the treatment of
choice for patients with TP or JP, depending on tumor size,
patient age, and other possibly intervening individualized
factors. TPs are usually categorized as Fisch A and B.
Surgical removal is the treatment of choice. Major post-
operative complications such as cranial nerve deficits are
usually not expected, but minor complications such as
postoperative conductive hearing loss may occur (45). In
cases categorized as Fisch A and B, a transmeatal approach
or a surgical approach via mastoidectomy, including
posterior tympanotomy and exposure of the facial nerve,
may be adequate (14). In some cases of TP categorized as
class B, a juxtacondylar approach might be necessary
(14,48).
There is an ongoing debate on treatment modalities when
it comes to JP (1,48). These masses are categorized as Fisch C
and D tumors (1,7,41). Thanks to development and
implementation of microsurgical techniques, it is possible
to resect these tumors completely, and local tumor control
can be achieved in 80–90% of cases (41,49,50). JP (Fisch
classification C and D) are usually resected via an
infratemporal approach. Tumors classified as Fisch C1,C 2
and De, Di1/2 may demand a variant of the juxtacondylar
approach (14). It is important to note that because these
tumors are adherent and occasionally invade cranial nerves
IX–XII, a higher complication risk concerning cranial nerve
deficits is anticipated for the postoperative outcome.
Patients may therefore experience problems, including
swallowing, voice, articulation, and shoulder weakness (7).
Consequently, further surgical procedures in an attempt to
correct these complications may be necessary in these
patients (1,7). In general, tumors classified as Fisch Di1/2
should be resected in a two-stage, team-approach procedure
involving neurosurgeons. This therapeutic option is not
available for patients categorized as Fisch Di3. In these cases,
palliative radiotherapy is advocated (14). Current literature
shows that the long-term success rate following surgical
therapy of JP is 72–95%; however, it should be noted that
comparison of results emerging from different studies is
difficult because parameters such as Fisch classification and
follow-up intervals are not consistent between studies (14).
NEUROSURGICAL ASPECTS OF SKULL BASE
PARAGANGLIOMAS
Skull base paragangliomas are rare tumors, even in major
referral neurosurgical centers, and they remain challenging,
due to their vascularized nature and deep intra-/extra-
cranial location. These tumors may involve the jugular bulb,
middle ear, petrous apex, clivus, carotid artery, infratem-
poral and posterior fossa. Despite their benign nature in the
majority of cases, these tumors tend to invade adjacent
structures, which may sometimes preclude complete resec-
tion of these lesions. In order to achieve a good clinical
outcome, close collaboration between ear, nose, and throat
(ENT) surgeons, neurosurgeons, and interventional neuror-
adiologists is of paramount importance.
The surgical approach is determined by the size and
anatomical location of the tumor. After careful analysis of
MRI and thin-section CT, the surgical approach is planned
with collaborative teamwork to address all aspects of the
tumor. The approach should be wide, as these tumors bleed
profusely on manipulation. The possibility of severe blood
loss needs to be considered in pre-operative planning. Pre-
operative embolization is generally recommended, espe-
cially for larger tumors. This will allow for safer surgery as a
result of less intraoperative blood loss and better visualiza-
tion of the structures.
Small tumors in the jugular bulb may be removed by a
transjugular approach. Other approaches include the
transmastoid and combined approaches (51). The intracra-
nial part of larger tumors is frequently best removed by an
infratemporal approach.
Intraoperative neuromonitoring is mandatory and should
include at least electromyography of the involved cranial
nerves. For tumors with major intracranial extension, motor,
sensory and auditory evoked potentials may become
necessary. The anesthesiologist needs to be informed about
this, and plan accordingly (no gas, no long-acting muscle
relaxants). The introduction of intra-operative neuromoni-
toring has significantly improved postoperative outcome,
particularly in sparing the facial nerve during skull-base
surgery (52).
HISTOPATHOLOGY
The HNPs described above have a similar histopathologic
appearance. Under the microscope, two types of cells
displaying typical nest-like or alveolar architectural pattern
are seen. Type I cells, or chief cells, are epitheloid cells often
with enlarged hyperchromatic nuclei and arranged in solid
groups called ‘‘Zellballen’’. These groups of chief cells are
surrounded by a flattened layer of type II cells or
sustentacular cells, which can be visualized by immunohis-
tochemical staining for S-100 protein (Figure 3). Type I and
type II cells characteristically lie within a dense network of
capillaries.
Chief cells may be quite uniform or may display
pronounced nuclear pleomorphism, such as bizarre and
huge multinucleated cells. They are immunohistochemically
positive for chromogranins (HNP shows strong expression
of chromogranin B, whereas chromogranin A is expressed
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24to a much lesser degree (53) and synaptophysin, yet are
negative to cytokeratin, in contrast to some pheochromocy-
tomas and paragangliomas of the filum terminale.
Unfortunately, nuclear pleomorphism, mitotic activity,
necrosis, or vascular or perineural invasion cannot predict
the biological behavior, as all these features may also be
found in benign HNPs.
Several attempts have been made to histologically
distinguish benign tumors from the rare malignant para-
ganglial tumors. These are based on scoring systems that
have been introduced for pheochromocytomas and para-
gangliomas of the retroperitoneum, although no scoring
system has been generally accepted as yet. The most
popular scoring system has been suggested by Thompson
Figure 3 - Histology and immunostaining of head and neck paragangliomas. (A) Demonstration of sustentacular cells by S-100 protein
in an HNP. The delicate net of sustentacular cells is surrounding the so-called Zellballen of chief cells (x200). (B) Complete
immunohistochemical negativity for SDHB strongly suggesting a SDHB germline mutation (x200). (C) Immunohistochemical
demonstration of SDHB protein in tumor cells, virtually excluding a germline mutation in SDHB (x200).
Table 3 - Molecular classification of head and neck paragangliomas (HNPs).
Syndrome VHL PGL1 PGL2 PGL3 PGL4 TMEM127
MIM ID 193300 168000 60650 605373 115310 613903
Inheritance Autosomal
Dominant
Autosomal
Dominant with
parent-of-origin
effect
Autosomal
Dominant with
parent-of-origin
effect
Autosomal
Dominant
Autosomal
Dominant
Autosomal
dominant
Gene name VHL SDHD SDHAF2 SDHC SDHB TMEM127
Protein function An ubiquitin ligase
protein; it plays a
role in the oxygen-
sensing pathway
One of two
membrane-
anchoring subunits
of complex II (SDH)
Mitochondrial
assembly factor
for complex II—
interacts
directly with
SDHA
One of two
membrane-
anchoring
subunits of
complex II (SDH)
The iron-sulfur
protein that form
together with
SDHA, the main
catalytic domain
of complex II
Endosomal
trafficking?; mTOR
regulation?
Locus 3p25-26 11q23 11q13.1 1q21 1p36 2q11
Age at diagnosis of
Pheochromocytoma mean
and range, in years
22 (5–67) 27 (5–65) unknown Extremely rare 34 (12–66) 43 (34–54)
Exons (n)//amino acids (n) 3/213 4/159 4/166 6/169 8/280 3/238
HNP (%) 0,5 41 73–86 100 8 1–2
Age at diagnosis HNP
Median (range, in years)
23 (7-39) 40 (12–74) 45 (15–65) 46 (13–73) 42 (9–75) 34
Pheo risk (%) 10-34 53 0 ,32 8 2 5
PG Abdominal extraadrenal
(%)
17 59 0 0 62 1–2
Multifocality (%) 56 55 0 9 11 33
Malignant (%) 4% 0 0 0 32 5
Clinical Phenotype Sympathetic
Noradrenergic
Parasympathetic,
occasionally
noradrenergic
Parasympa thetic Parasympa thetic Noradrenergic Sympathetic
Noradrenergic
Associated tumors Eye and CNS
hemangioblastomas,
clear cell
renal cancer, islet cell
tumors,
endolymphatic sac
tumors
of the inner ear
Rarely Papillary
thyroid cancer,
GIST
GIST GIST Rarely renal cell
cancer GIST
Adapted from Bausch et al. (73), Hensen et al. (74) and Neumann and Eng (75).
CNS = central nervous system; GIST = gastrointestinal stromal tumor, mTOR = mammalian target of rapamycin; PGL = Paraganglioma syndrome;
SDHAF2 = succinate dehydrogenase complex assembly factor 2; TMEN127 = transmembrane protein 127.
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25(54), and includes a variety of criteria, such as cellular and
nuclear features, growth patterns, or occurrence of necrosis.
It has to be emphasized that only the occurrence of lymph
node and/or distant metastases are the ultimate criteria for
malignancy. Morphologic demonstration of tumor invasion
to adjacent structures including bone does not indicate
biologic malignancy. Isolated tumor nodules in the vicinity
of the main tumor may represent multicentricity of the
HNP. Such tumor nodules can only be interpreted as lymph
node metastases if they are embedded into (remnants of)
lymphatic tissue.
Immunochemical staining with antibodies against SDHB
protein has been found to be associated with germline
mutations of the SDHB, SDHC, and SDHD genes (Figures 3A
and B) (55). As a result, immunostaining has become a
screening method to select patients for subsequent mole-
cular genetic testing. The value of immunostaining against
SDHB and other proteins is currently under investigation,
and the importance for routine histopathology and genetics
will be corroborated in expected additional analyses (56).
OUTCOME AND CHALLENGES
Management of head and neck paragangliomas is
challenging for every physician, especially in cases of
multiple paragangliomas or tumors in an advanced stage.
The outcome mainly depends on the stage of tumor at initial
presentation.
For Shamblin type I and type II CBTs, the peri- and
postoperative risk of neurovascular complications is low
(57). Complication rate increases strongly for Shamblin type
III CBTs (57,58). The current literature shows serious
postoperative complications only in 0–2.3% of patients with
Shamblin type I and II tumors, while this figure increases to
7–35.7% for patients with a Shamblin type III tumor (57–59).
For JP, surgical control is achieved in about 70–86% of
patients, even in Fisch class C and D tumors (45,60–62).
Although postoperative functional deficit of the cranial
nerves occurs, patients seem to be able to cope with the new
limitations within two years and get back to a normal social
life (60). While total resection of the tumors should be
performed as a curative treatment for paragangliomas
(62,63), a subtotal removal may be required to preserve
cranial nerve function. In such cases, subtotal tumor
resection, combined with gamma-knife surgery or radiation
therapy, has proved to be a safe and effective treatment
modality (61,64–66). In the elderly, it is important to weigh
up the possible disabilities after surgical therapy, so a more
conservative treatment concept might be preferred (61,67).
The outcome after surgical removal of TP (Fisch type A) is
normally very good, with preservation of hearing in more
than 90% of cases (63,68–70); therefore, surgical resection of
these tumors is the therapy of choice (63,68,70).
VPs are special. They originate from the vagus nerve, so
surgical removal of these tumors will be associated with a
loss of vagal nerve function in the vast majority of cases
(39,71,72) despite the fact that the nerve is kept anatomically
intact (72). The immediate consequences would be hoarse-
ness, dysphagia, and aspiration. The situation is even worse
for extensive VPs, where additional cranial nerve deficits (in
about 50–60% of patients) are seen because of the close
proximity of the tumor in the jugular foramen to cranial
nerves IX, XI, and XII (39,71,72). Bradshaw and Jansen
described a group of 40 patients with VPs, in whom a
wait-and-scan policy was chosen (39). Only three of these
patients developed cranial nerve palsy during an average
follow-up of 8.5 years. It should be kept in mind that the
morbidity of a cranial nerve palsy caused by surgery is
higher than the morbidity caused by slow fading of the
nerve function through the tumor (72). Hence, surgical
removal of VPs should be weighed against the patient’s age,
size of the tumor, predicted tumor growth and cranial nerve
function (72).
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